Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer
CHEMOTHERAPY(2016)
摘要
Background: We investigated the efficacy and safety of biweekly irinotecan and cisplatin (IP) as first-line treatment in advanced gastric cancer patients. Methods: Irinotecan 125 mg/m(2) on day 1 and cisplatin 60 mg/m 2 on day 2 were administrated every 14 days. UGT1A1*28/*6 and toxicities were analyzed. Results: Forty-one eligible patients were enrolled. Fifteen patients, who were defined as the high-dose group, received starting doses of irinotecan 125 mg/m(2). Twenty-six patients, who were defined as the low-dose group, received starting doses of irinotecan 80 mg/m(2) and cisplatin 50 mg/m(2). The response rate was 53.3% in the irinotecan high-dose group and 53.8% in the irinotecan lowdose group. The most common grade 3/4 toxicity was neutropenia (68.3%). No significant difference in grade 3/4 neutropenia was found between patients with the wild-type genotype and those with variant genotypes for UGT1A1*28 or UGT1A1*6. Conclusions: The combination of biweekly irinotecan 80 mg/m(2) and cisplatin 50 mg/m 2 was active and tolerable. The role of the UGT1A1 genotype in clinical toxicity of an IP regimen requires further investigation. (C) 2016 S. Karger AG, Basel
更多查看译文
关键词
Gastric cancer,Irinotecan,Cisplatin,UGT1A1
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要